Table 2 Comparison of clinical, laboratory, and molecular data for AML-EP and AML without EP

From: A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria

 

AML-EPa (N = 134)

AML without EPa (n = 155)

Significance

Gender (M/F)

103/43

93/57

NS

Age

64.4

65.3

NS

AML-MRC

91

98

NS

- Clinical history

56

50

NS

- Karyotype

25

42

 

- Morphology only

10

6

 

T-AML

20

25

 

AML, NOS

23

24

 

BM blasts (%)

24.8

51.2

p < 0.0001

BM erythroid cells (%)

55.6

14.2

p < 0.0001

PB WBC

3.0

18.9

p < 0.0001

Hemoglobin (g/dL)

9.0

9.1

NS

Platelets

67.8

88.9

NS

PB Blasts (%)

21.7

29.8

p = 0.002

CG risk group (UKMRC)

Intermediate

87 (59%)

73 (48%)

p = 0.03

Adverse

59 (41%)

81 (52%)

 

Received HSCT (%)

33 (24%)

49 (32%)

NS

Molecular data (mutation detected/cases tested)

NPM1 b

3/82 (3.6%)

8/108 (7.4%)

NS

FLT3

3/101 (2.9%)

11/107 (10.3%)

p = 0.027

TP53

15/34 (44%)

21/88 (24%)

p = 0.045

NRAS/KRAS

4/64 (6.2%)

16/41 (39%)

p = 0.0001

IDH1/2

8/38 (21%)

12/35 (34%)

NS

EZH2

1/29 (3%)

4/30 (13%)

NS

ASXL1

3/26 (11.5%)

8/33 (24%)

NS

  1. AML-EP AML with erythroid predominance, AML-MRC AML with myelodysplasia-related changes, t-AML therapy-related myeloid neoplasm, BM bone marrow, PB peripheral blood, NS not significant, HSCT hematopoietic stem cell transplant, CG cytogenetic
  2. aBoth AML-EP and AML without EP groups exclude cases of AML-RGA and blast phase of MPN
  3. bIncludes NPM1 mutated t-AML, AML-MRC by clinical history, and AML-MRC due to cytogenetic changes
Back to article page